ストックスクリーナーアプリを入手
21.62
1.03%
0.22
アフターアワーズ：
21.62
前日終値:
$21.40
開ける：
$21.39
24時間の取引高:
1.03M
Relative Volume:
0.76
時価総額：
$1.88B
収益：
$139.71M
当期純損益:
$-209.36M
株価収益率:
-7.3041
EPS:
-2.96
ネットキャッシュフロー:
$-160.60M
1週間 パフォーマンス:
+4.19%
1か月 パフォーマンス:
+5.82%
6か月 パフォーマンス:
+33.54%
1年 パフォーマンス:
+50.35%
1日の値動き範囲:
$21.00
$21.91
1週間の範囲:
$19.21
$22.68
52週間の値動き範囲:
$8.58
$22.73
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
名前
Syndax Pharmaceuticals Inc
セクター
電話
781-419-1400
住所
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
21.62 | 1.86B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-16 | 再開されました | H.C. Wainwright | Buy |
| 2025-09-10 | 再開されました | Stifel | Buy |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-08-05 | 繰り返されました | BTIG Research | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-06-28 | 開始されました | Jefferies | Buy |
| 2024-01-31 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-10-25 | 開始されました | BofA Securities | Buy |
| 2023-10-11 | 開始されました | Goldman | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-11 | 開始されました | Guggenheim | Buy |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2023-01-03 | 開始されました | JP Morgan | Overweight |
| 2022-07-28 | 再開されました | B. Riley Securities | Buy |
| 2022-04-11 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-15 | 開始されました | Goldman | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-25 | 開始されました | Citigroup | Buy |
| 2021-02-18 | 開始されました | B. Riley Securities | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-05-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-01-04 | 開始されました | Robert W. Baird | Outperform |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 開始されました | FBR & Co. | Outperform |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2016-10-07 | 開始されました | Guggenheim | Buy |
| 2016-03-28 | 開始されました | Citigroup | Buy |
| 2016-03-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-03-28 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Market Wrap: Is Syndax Pharmaceuticals Inc. forming a double bottomWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Syndax Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-03-03 - Seeking Alpha
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Pipeline Progress Or Stretching Recent Share Gains - simplywall.st
SNDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SNDX Receives Buy Rating as Citigroup Raises Price Target to $57 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $57.00 Price Target at Citigroup - MarketBeat
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Bitget
Syndax’s Third FDA Win Accelerates Shift To Multi Product Revenues - Sahm
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript - Insider Monkey
Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX) - The Globe and Mail
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance
Syndax (SNDX) Q4 2025 Earnings Call Transcript - Intellectia AI
Syndax Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Syndax Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Discipline and Rules-Based Execution in SNDX Response - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals (SNDX) Reports Strong 2025 Earnings and Growth Prospects - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results - MarketBeat
Syndax Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax (SNDX) Projects Stable Operating Expenses and Path to Pro - GuruFocus
Syndax (SNDX) Exceeds Revenue Expectations, Anticipates Continued Growth - GuruFocus
Syndax Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q4 2025 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q4 Revenue $68.7M, vs. FactSet Est of $64.3M - marketscreener.com
BRIEF-Syndax Pharmaceuticals Q4 Operating Expenses USD 131.276 Million - TradingView
Cancer drug maker Syndax posts $172M sales, eyes profitability - Stock Titan
Syndax faces earnings test as cancer drug launches accelerate By Investing.com - Investing.com UK
Syndax faces earnings test as cancer drug launches accelerate - Investing.com India
Syndax: Overview of Fourth Quarter Financial Results - Bitget
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Syndax Pharmaceuticals, Inc. announces that patient enrollment has been completed for its Phase II clinical trial of Axatilimab for idiopathic pulmonary fibrosis (IPF). - Bitget
VIX Spike: Is Syndax Pharmaceuticals Inc stock showing strong momentumBull Run & High Yield Equity Trading Tips - baoquankhu1.vn
Biotech CEO plans three March investor Q&As in Boston and Miami - Stock Titan
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday - Defense World
Aberdeen Group plc Grows Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. a speculative investment2025 Price Momentum & Accurate Trade Setup Notifications - mfd.ru
Earnings Miss: Does Syndax Pharmaceuticals Inc. have strong fundamentalsQuarterly Investment Review & Safe Capital Investment Plans - mfd.ru
Can Syndax Pharmaceuticals Inc. stock double in the next yearInsider Selling & Precise Trade Entry Recommendations - mfd.ru
Syndax Pharmaceuticals (SNDX) Stock Analysis: An 88% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call ... - Bluefield Daily Telegraph
Syndax to Announce Fourth Quarter and Full Year 2025 - GlobeNewswire
Cancer drug maker Syndax to review 2025 results in Feb. 26 earnings call - Stock Titan
Syndax Pharmaceuticals Highlights Revuforj, Niktimvo Sales Surge and 2026 Milestones at Guggenheim Conf - Defense World
Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation - Yahoo Finance
Behavioral Patterns of SNDX and Institutional Flows - Stock Traders Daily
Syndax Pharmaceuticals Inc (SNDX) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):